Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700227 · ClinicalTrials.gov registry record · NA
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer
A NA study, sponsored by Varian, a Siemens Healthineers Company.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT05700227 is a NA study that was terminated before completion, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 2 participants.
The verdict
NCT05700227, a NA study, was terminated before completion, sponsored by Varian, a Siemens Healthineers Company.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxicity compared with the historically reported rate for non-adaptive radiation therapy. The Common Terminology Criteria for Adverse Events (CTCAE) version 5 assessment tool will be utilized.
Interventions
- RADIATION Daily Adaptive External Beam Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2024-05-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700227
The ClinicalTrials.gov registry entry for NCT05700227 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Varian, a Siemens Healthineers Company, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daily Adaptive External Beam Radiation Therapy is the first listed.
NCT05700227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05700227 about?
NCT05700227 is a clinical study titled "Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer". This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxic...
What is the current status of trial NCT05700227?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2023-02-02. Estimated completion is 2024-05-09.
What interventions are being tested in trial NCT05700227?
The interventions under investigation include: Daily Adaptive External Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05700227?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.